As patients diagnosed with central precocious puberty at a younger age are more likely to be started on treatment with GnRH treatment tout-court, the median age upon reported onset of puberty in the selected population (7.48 years, IQR: 6.81–8.13) mirrors the class of patients that benefit the most from the clinical outcomes of the present analysis. This evidence concerns the gene GNRH1 and central precocious puberty.